Literature DB >> 8231253

Infection of leukaemic B lymphocytes by Epstein Barr virus.

M G Doyle1, D Catovsky, D H Crawford.   

Abstract

Epstein-Barr virus (EBV) infection of B lymphocytes in vitro gives rise to immortalized lymphoblastoid cell lines. Previous reports have shown that chronic lymphocytic leukaemia (CLL) cells, although infectable by EBV, are resistant to immortalization (1-4), although a small number of CLL cell lines have been reported (5-7). In the present study we have analysed early events occurring after EBV infection in 16 CLL samples. Out of 16 samples, 15 could be infected by the virus and expressed the full EB viral nuclear antigen (EBNA) complex but only one out of 16 expressed the latent membrane protein (LMP). The five CLLs in which we could investigate the presence of viral episomes showed circularized EBV by 16 hours after infection. The sequence of EBNA expression and genome circularization mirrored that seen in normal B cells, although genome amplification was not detected. The only CLL sample which expressed LMP after EBV infection was induced to proliferate for 2-3 weeks, but no cell line was established. Immortalized cell lines were obtained from three out of 16 samples tested, but all were polyclonal for light chain expression and had arisen from the CD5-negative, normal B-cell population. Thus the inability of EBV to induce proliferation of most CLL cells correlated with the absence of LMP expression which is invariably expressed during immortalization of normal B cells. This novel type of restricted gene expression could be compatible with evasion of host immune responses and consequent long-term survival of the cell in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8231253

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia.

Authors:  A Veronese; F Pepe; J Chiacchia; S Pagotto; P Lanuti; S Veschi; M Di Marco; A D'Argenio; I Innocenti; B Vannata; F Autore; M Marchisio; D Wernicke; F Verginelli; G Leone; L Z Rassenti; T J Kipps; R Mariani-Costantini; L Laurenti; C M Croce; R Visone
Journal:  Leukemia       Date:  2014-04-15       Impact factor: 11.528

Review 2.  To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis.

Authors:  Alexander M Price; Micah A Luftig
Journal:  PLoS Pathog       Date:  2015-03-19       Impact factor: 6.823

3.  Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization.

Authors:  Maroulio Pertesi; Perrine Galia; Nicolas Nazaret; Maxime Vallée; Laurent Garderet; Xavier Leleu; Hervé Avet-Loiseau; Matthieu Foll; Graham Byrnes; Joel Lachuer; James D McKay; Charles Dumontet
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

4.  N(6)-methyladenosine-binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay.

Authors:  Tian-Liang Xia; Xingyang Li; Xueping Wang; Yun-Jia Zhu; Hua Zhang; Weisheng Cheng; Mei-Ling Chen; Ying Ye; Yan Li; Ao Zhang; Dan-Ling Dai; Qian-Ying Zhu; Li Yuan; Jian Zheng; Huilin Huang; Si-Qi Chen; Zhi-Wen Xiao; Hong-Bo Wang; Gaurab Roy; Qian Zhong; Dongxin Lin; Yi-Xin Zeng; Jinkai Wang; Bo Zhao; Benjamin E Gewurz; Jianjun Chen; Zhixiang Zuo; Mu-Sheng Zeng
Journal:  EMBO Rep       Date:  2021-02-19       Impact factor: 8.807

5.  EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency.

Authors:  Eva Klein; Noémi Nagy; Abu Eahsan Rasul
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.